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Mean (sd) natural log-transformed biomarker concentrations for both groups at baseline and follow-up
Baseline Exercise
Group (n¼9)
Baseline No
Exercise
Group (n¼8)
Follow-up
Exercise
Group (n¼9)
Follow-up No
Exercise
Group (n¼7)
Adjusted Between-groups
Change Difference (95% CI)
p-value
URINARY MARKERS
uCTX-II (log ng/mmol creatinine) 5.40 (0.81) 5.97 (0.57) 5.32 (0.93) 6.25 (0.68) -0.33 (-0.71, 0.04) 0.11
uC2C (log ng/mmol creatinine) 2.45 (0.68) 2.46 (0.76) 2.57 (0.81) 2.71 (0.58) -0.13 (-0.84, 0.58) 0.73
SERUM MARKERS
sHA (log U/L) 3.47 (0.93) 3.80 (0.96) 3.26 (1.13) 4.21 (0.86) -0.79 (-1.67, 0.08) 0.10
sCOMP (log U/L) 2.20 (0.21) 2.26 (0.17) 2.11 (0.24) 2.36 (0.13) -0.16 (-0.30, -0.02) 0.04
sCPII (log U/L) 6.56 (0.19) 6.44 (0.53) 6.50 (0.36) 6.71 (0.40) -0.34 (-0.93, 0.24) 0.27
RATIOS
[uCTX-II]:sCPII -1.16 (0.74) -0.46 (0.49) -1.18 (0.97) -0.46 (0.81) 0.01 (-0.63, 0.66) 0.97
[uC2C]:sCPII -4.11 (0.69) -3.98 (1.19) -3.93 (0.98) -4.01 (0.73) 0.22 (-0.59, 1.03) 0.61
[sHA]:sCPII -3.09 (0.99) -2.64 (0.87) -3.24 (1.37) -2.50 (0.77) -0.45 (-1.43, 0.53) 0.39
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SYNOVIAL FLUID PREPARATION TO IMPROVE IMMUNOASSAY
PRECISION FOR BIOMARKER RESEARCH USINGMULTIPLEX PLATFORMS
C. Jayadev, R. Rout, W. Jackson, A. Price, P. Hulley. Univ. of Oxford, Oxford,
UNITED KINGDOM
Purpose: Synovial ﬂuid (SF) reﬂects the biological milieu of the joint and is
a potentially important source of biomarkers in osteoarthritis (OA). OA joints
usually do not offer enough SF volume for analysis of multiple markers in
a single sample by conventional enzyme-linked immunosorbent assays
(ELISA). Newer platforms i.e. Luminex and Meso Scale Discovery (MSD)
enable multiplex analysis in small (50ml) volumes. However, SF analysis is
challenging due to its complex matrix and viscous non-Newtonian nature.
The aim of the study was to optimise SF sample preparation for the best
assay precision during multiplex analysis by the Luminex and MSD
platforms.
Methods: SF was harvested from 16 patients with end-stage knee OA at
arthroplasty. All samples underwent identical processing and preparation
(Figure 1).
ĂDilutions were made with the manufacturer's assay diluent. Hyaluronic
acid (HA) was digested by treatment with 2mg/ml bovine testicular hyal-
uronidase (madeup in assaydiluent) for 1hr at RT. This included an effective
2-fold sample dilution. Experiments (Table 1) were conducted according to
the manufacturer's protocol. Samples were analysed in triplicate.Table 1
Experiment Summary
Platform Platform Info. Assay Details
Luminex Polystyrene bead system Inﬂammatory 10-plex
IL8, IL10, GMCSF, IL5,
Luminex Magnetic bead system IL6 single-plex
Meso Scale Discovery Multi-spot
Electrochemiluminescence
Inﬂammatory 4-plex (Bead events per target (for Luminex assays only) and the coefﬁcient of
variation (CV) of the calculated concentration for sample triplicates were
compared for each pre-treatment protocol. Luminex data generated from
<35 bead events per target is not acceptable. At least 50 bead events are
recommended. Intra-assay precision with a CV <25% is a widely used
acceptance criterion. Matched/repeat measure statistical tests were used
when possible as each sample was assayed after each pre-treatment.
P<0.05 was considered signiﬁcant.
Results: Luminex bead counts: In the polystyrene bead Luminex 10-plex,
the proportion of usable samples (2 replicates with 35 bead events)
was signiﬁcantly greater when samples were digested (McNemar's test,
p<0.001 for each target). In the magnetic bead Luminex IL6-plex, all
samples were usable with 50 bead events in every well for each prepa-
ration protocol.
Assay Precision:
Polystyrene bead Luminex 10-plex: Only IL6 and IL8 were above the limit
of quantiﬁcation. Comparison of the overall group mean %CV for all
usable samples was signiﬁcantly lower in digested than neat samples for
both IL-6 (p¼0.007, Mann-Whitney test) and IL-8 (p¼0.004, two-tailed t-
test).
Magnetic bead Luminex IL6-plex: Every digested samples had an intra-assay
CV <15% (group mean 6.7%). Each sample's intra-assay CV was signiﬁ-
cantly greater if it was neat or diluted (p¼0.0195, repeated measures
ANOVA; p< 0.05 for neat, 2-fold & 4-dilution by Newman-Keuls post-hoc
comparisons).
Meso Scale Discovery:For relatively abundant targets i.e. IL6 & IL8, all
but 2 samples had an intra-assay CV <25% for each pre-treatment.
There was no signiﬁcant difference in intra-assay CV for samples
under each different pre-treatment (repeat measures ANOVA). For
TNF-a, only digestion produced intra-assay CVs <25% for every
sample. However, the improved %CV of digested samples did not
reach statistical signiﬁcance (repeat measures ANOVA). ILb levels
were below the linear part of the standard curve at the lower limit of
quantiﬁcation.
Conclusions:The magnetic bead Luminex system maximises bead events
per target irrespective of sample preparation.
SF digestionwith 2mg/ml hyaluronidase (with 2-fold dilution) gives better
intra-assay precision for polystyrene and magnetic bead Luminex assays
than dilution alone. MSD assays for abundant targets show good precision
irrespective of sample pre-treatment. However, digestion may offer better
precision for less expressed targets i.e. TNF-a and is preferable to large
dilutions that may take the target below the dynamic range WeTreatment Protocols Number of Samples
(IL1b, IL6, TNFa, IL4,
IFNg & IL2)
Neat Digested 16
Neat 2xDilution
4xDilution Digested
7 (of 16)
IL1b, TNFa, IL6 & IL8) Neat 2xDilution
4xDilution Digested
7 (of 16) Same as above
Table 2
Average group intra-assay %CV for Sample Preparation Method.
Neat Digested 2xDilution 4xDilution
Luminex Polystyrene (n¼16) IL6 22.4 (IQR 18.8-29.9) (n¼7) 6.1 (IQR 3.8-13.7) (n¼15)
IL8 26.5 (SD 16.3) (n¼7) 4.8 (SD 1.8) (n¼13)
Luminex Magnetic (n¼7) IL6 28.2 (SD 9.4) 6.7 (SD 6.0) 26.0 (SD 16.5) 20.8 (SD 16.6)
Meso Scale Discovery (n¼7) IL6 6.6 (SD 2.5) 7.2 (SD 8.0) 13.3 (9.0) 14.2 (SD 13.0)
IL8 10.2 (SD 6.8) 10.9 (SD 6.2) 15.2 (SD 9.6) 15.8 (SD 13.2)
TNF-a 25.4 (SD 14.2) 14.5 (SD 5.9) 18.8 (SD 19.4) 27.0 (SD 16.4)
IL1b 55.3 (SD 37.6) 69.8 (SD 27.9) 67.6 (SD 29.0) 124.1 (SD 57.1)
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S85recommend sample pre-treatment with 2mg/ml hyaluronidase (& 2-fold
dilution) for multiplex synovial ﬂuid analysis.
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A WIDE ASSOCIATION STUDY OF PREDICTORS OF FUTURE KNEE PAIN:
DATA FROM THE OSTEOARTHRITIS INITIATIVE
J.I. Galván-Tejada 1, A. Martinez-Torteya 1, S. Totterman 2, J. Farber 2,
V. Treviño 1, J.G. Tamez-Pena 1. 1 ITESM, Monterrey, Nuevo Leon, Mexico;
2Qmetrics Technologies, Rochester, NY, USA
Purpose: Pain is a common symptom of knee OA. The presentation of
the symptom is protean, and varies from person to person and from
disease stage to disease stage. WOMAC pain sub scores assess a sub-
ject's pain while: 1) In bed; 2) Walking; 3) Climbing stairs; 4) Standing;
and 5) Lying down. These ﬁve categories reﬂect, presumably, different
etiologies of pain. To better understand the etiology of pain in these
settings, the OAI has been capturing thousands of variables (variable is
a speciﬁc clinical data) in OA patients; hopefully, evaluation of these
variables will allow a better understanding of OA, and establish
predictors of OA related pain. The objective of this work was to use
automated wide association tools to determine which OAI variables,
singularly or in association with other variables, best predict future OA
related pain.
Methods: The 4786 OAI enrolled subjects and the 1226 variables of the
OAI baseline clinical datasets (OAI:0.2.2) and the 36 month WOMAC pain
sub-score data (OAI:5.2.1) were explored in this study. Baseline variables
with more than 10% of missing information were removed. Subjects with
36 month missing WOMAC pain data were removed. Therefore, only
4204 patients and 629 variables were included in this study. Further-
more, to explore the no-pain related sources of future knee pain all
baseline pain related variables were removed. The max value from the
left and right knee pain sub-scores were used as the outcome variable to
be predicted by a ﬁve variable multidimensional nearest centroid clas-
siﬁer using BIOMATEC (Monterrey, Mexico). The top predictor variables
of each pain sub-score were selected after generating 5000 models using
a 33%, 67% split between training and testing sets. Once the top variables
were selected, linear models and R software were used to get the
signiﬁcance of those variables in predicting the 36 month WOMAC pain
scores.
Results: All linear regression models were highly signiﬁcant (p<1.0-
10) with R2 ranging from 0.199 to 0.328. Left knee catch or hand
up when moving, folate supplements, having a symptomatic knee,
physical scale and right knee stiffness score predicted pain while lying
down. Health limiting moderate activities, WOMAC knee stiffness, left
knee KOOS symptoms and blood pressure predicted pain in Bed.
Climbing stairs pain was predicted by lack of conﬁdence in knees and
WOMAC disability score. Health limiting moderate activities, left knee
swelling, lack of conﬁdence in knees and WOMAC stiffness score
predicted pain while walking. Standing pain was predicted by KOOS
symptom score and 400 meters walk time physical test.
Conclusions: Wide association studies can be very helpful in data
mining the OAI databases. These tools were used to explore models
predictive of the 36 month pain sub scores and yielded highly pre-
dicting models. Therefore, three year pain prognosis is possible using
clinical data.Ă
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URINARY CTX-II IS MORE USEFUL IN POSTMENOPAUSALWOMEN THAN
IN MEN TO DETECT RADIOLOGICAL KNEE OA: THE MATSUDAI KNEE
OSTEOARTHRITIS SURVEY
H. Yamagiwa 1, Y. Takahashi 2, T. Hayami 3, N. Tanishi 4, G. Omori 5,
Y. Koga 6, N. Endo 1. 1Dept. of Orthop. Surg., Niigata Univ., Niigata, Japan;
2Dept. of Orthop. Surg., Niigata Prefectural Central Hosp., Joetsu, Japan;
3Dept. of Orthop. Surg., Saiseikai Niigata Daini Hosp., Niigata, Japan;
4Dept. of Orthop. Surg., Niigata Rosai Hosp., Joetsu, Japan; 5Ctr. for
Transdisciplinary Res., Niigata Univ., Niigata, Japan; 6Dept. of Orthop. Surg.,
Niigata Med. Ctr. Hosp., Niigata, Japan
Purpose: Biochemical markers of cartilage degradation are important
indices to evaluate knee osteoarthritis (OA). The correlation between
radiological knee OA and urine CTX-II (C-terminal crosslinking telopeptide
of collagen type II: uCTX-II) needs to be evaluated how this marker is
useful in the health check-up in a large population-based study.
Methods: We have performed the epidemiological knee survey in a rural
Japanese population at the Matsudai district in Niigata Prefecture, Japan
since 1979. In 2010 (6th survey), a cross-sectional study of biomarkers was
conducted with informed consent. Urine specimens were collected from
942 subjects, and uCTX-II was measured using Urine CartiLaps EIA. The
data more than 1000 ng/mmmol Cre were considered as outliers. Subjects
with oral administration of bisphosphonate, fracture within a year, or TKA
were excluded. Standing knee AP X-rays were obtained and graded
according to the Kellgren-Lawrence (K-L) classiﬁcation. The 60- to 79-year-
old subjects were selected and then divided by gender (260 female and 276
male) and OA grade (K-L Grade 0,1, Grade 2, and Grade 3,4 groups). The
levels of uCTX-II were compared between three OA grade groups using
Kruskal-Wallis test and Mann-Whitney U-test. The subjects were stratiﬁed
into quartiles based on the values of uCTX-II, and proportion of OA grades
in each quartile was compared using chi-square test. In addition, to
